HK1200169A1 - Compounds used in the synthesis of oxazolidinones - Google Patents

Compounds used in the synthesis of oxazolidinones

Info

Publication number
HK1200169A1
HK1200169A1 HK15100600.5A HK15100600A HK1200169A1 HK 1200169 A1 HK1200169 A1 HK 1200169A1 HK 15100600 A HK15100600 A HK 15100600A HK 1200169 A1 HK1200169 A1 HK 1200169A1
Authority
HK
Hong Kong
Prior art keywords
oxazolidinones
synthesis
compounds used
compounds
Prior art date
Application number
HK15100600.5A
Other languages
English (en)
Chinese (zh)
Inventor
Carrie A Costello
Jaqueline A Ware
Robert J Duguid
Original Assignee
Trius Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trius Therapeutics Inc filed Critical Trius Therapeutics Inc
Publication of HK1200169A1 publication Critical patent/HK1200169A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
HK15100600.5A 2008-10-10 2015-01-19 Compounds used in the synthesis of oxazolidinones HK1200169A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10446908P 2008-10-10 2008-10-10

Publications (1)

Publication Number Publication Date
HK1200169A1 true HK1200169A1 (en) 2015-07-31

Family

ID=41382395

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15100600.5A HK1200169A1 (en) 2008-10-10 2015-01-19 Compounds used in the synthesis of oxazolidinones
HK17105843.9A HK1232221A1 (zh) 2008-10-10 2017-06-13 製備噁唑烷酮類的方法及含有噁唑烷酮類的組合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK17105843.9A HK1232221A1 (zh) 2008-10-10 2017-06-13 製備噁唑烷酮類的方法及含有噁唑烷酮類的組合物

Country Status (13)

Country Link
US (2) US8604209B2 (es)
EP (2) EP2346858B1 (es)
JP (1) JP5773875B2 (es)
KR (1) KR101674146B1 (es)
CN (2) CN106220621B (es)
AU (1) AU2009303301B2 (es)
CA (1) CA2738671C (es)
ES (2) ES2748505T3 (es)
HK (2) HK1200169A1 (es)
MX (2) MX2011003820A (es)
RU (2) RU2659792C1 (es)
SG (2) SG10201702946RA (es)
WO (1) WO2010042887A2 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100854211B1 (ko) * 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
EP2346858B1 (en) 2008-10-10 2019-08-07 Merck Sharp & Dohme Corp. Methods for preparing oxazolidinones and compositions containing them
ES2734724T3 (es) 2009-02-03 2019-12-11 Merck Sharp & Dohme Forma cristalina de dihidrogenofosfato de (R)-3-(4-(2-(2-metiltetrazol-5-il)piridin-5-il)-3-fluorofenil)-5-hidroximetiloxazolidin-2-ona
US8580767B2 (en) * 2009-05-28 2013-11-12 Trius Therapeutics, Inc. Oxazolidinone containing dimer compounds, compositions and methods to make and use
US20120065170A1 (en) 2010-09-10 2012-03-15 Micurx Pharmaceuticals, Inc. Antimicrobial Cyclocarbonyl Heterocyclic Compounds For Treatment Of Bacterial Infections
WO2016009401A2 (en) * 2014-07-18 2016-01-21 Dr. Reddy's Laboratories Limited Preparation of tedizolid phosphate
CN105367547B (zh) * 2014-08-19 2019-04-23 北京桦冠生物技术有限公司 一种噁唑啉酮抗生素的新合成工艺
CN106928214A (zh) * 2014-09-17 2017-07-07 博瑞生物医药(苏州)股份有限公司 一种噁唑烷酮类化合物及其中间体的制备方法
WO2016041505A1 (zh) * 2014-09-17 2016-03-24 正大天晴药业集团股份有限公司 一种磷酸特地唑胺、其中间体以及它们的制备方法
CN104327119A (zh) * 2014-10-17 2015-02-04 苏州明锐医药科技有限公司 磷酸泰地唑胺的制备方法
WO2016088102A1 (en) * 2014-12-05 2016-06-09 Sun Pharmaceutical Industries Limited Processes for the preparation of tedizolid phosphate and its intermediates
WO2016088100A1 (en) * 2014-12-05 2016-06-09 Sun Pharmaceutical Industries Limited Processes for the preparation of tedizolid phosphate and its intermediates
WO2016088103A1 (en) * 2014-12-05 2016-06-09 Sun Pharmaceutical Industries Limited A process for the preparation of tedizolid phosphate
WO2016088101A1 (en) * 2014-12-05 2016-06-09 Sun Pharmaceutical Industries Limited Processes for the preparation of tedizolid phosphate and its intermediates
CN104558034A (zh) * 2015-01-21 2015-04-29 齐鲁制药有限公司 磷酸特地唑胺二钠盐的新晶型及其制备方法
CN105837634B (zh) * 2015-01-30 2020-09-04 上海创诺制药有限公司 一种泰地唑胺磷酸酯结晶体及其制备方法
CN104592218B (zh) * 2015-02-13 2015-11-04 江苏欧信医药化工有限公司 一种泰地唑胺的合成方法
CN104892592A (zh) * 2015-03-30 2015-09-09 成都惟新医药科技有限公司 一种泰地唑胺的制备方法
CN106146485B (zh) * 2015-04-01 2021-04-30 上海迪赛诺化学制药有限公司 一种制备泰地唑胺的方法及其得到的泰地唑胺结晶体
CN106279281B (zh) * 2015-05-15 2018-08-03 重庆圣华曦药业股份有限公司 噁唑烷酮类抗菌素泰地唑胺磷酸酯的精制方法
CN106279282B (zh) * 2015-05-21 2019-08-23 博瑞生物医药(苏州)股份有限公司 一种磷酸特地唑胺的纯化方法
CN106317114B (zh) * 2015-07-02 2018-11-20 南京优科制药有限公司 一种磷酸特地唑胺的制备方法
CN105131037B (zh) * 2015-07-28 2017-05-03 济南爱思医药科技有限公司 一种高纯度泰地唑胺磷酸酯的制备方法
CN106632298B (zh) * 2015-11-03 2021-06-01 上海科胜药物研发有限公司 一种泰地唑胺的制备方法及其中间体
KR101855334B1 (ko) 2015-12-11 2018-06-08 에스티팜 주식회사 옥사졸리디논 유도체의 중간체 제조방법
CN105418681A (zh) * 2015-12-15 2016-03-23 南京艾德凯腾生物医药有限责任公司 一种磷酸特地唑胺的制备方法
CN107488188B (zh) * 2016-06-12 2019-03-15 重庆圣华曦药业股份有限公司 一种制备特地唑胺关键中间体的合成方法
CN106146560B (zh) * 2016-07-12 2019-02-01 扬子江药业集团有限公司 一种高纯度磷酸特地唑胺的精制方法
CN106432182B (zh) * 2016-09-06 2019-04-30 铜仁学院 特地唑胺中间体的合成方法
CN106565680A (zh) * 2016-10-31 2017-04-19 瑞阳制药有限公司 特地唑胺杂质及其制备方法
CN108059624A (zh) * 2016-11-08 2018-05-22 上海医药工业研究院 用于制备咔哒唑胺关键中间体的制备方法
CN106632240A (zh) * 2016-11-25 2017-05-10 山东轩德医药科技有限公司 一种2‑甲基‑5‑(5‑溴吡啶‑2‑基)四氮唑的制备方法
CN106699730A (zh) * 2016-12-23 2017-05-24 山东轩德医药科技有限公司 2‑甲基‑5‑(5‑溴吡啶‑2‑基)四氮唑的制备方法
CN107722056A (zh) * 2017-10-31 2018-02-23 重庆华邦胜凯制药有限公司 磷酸特地唑胺的制备方法
WO2019118311A1 (en) 2017-12-13 2019-06-20 Merck Sharp & Dohme Corp. Pharmaceutical compositions of tedizolid phosphate
CN110804038B (zh) * 2018-08-06 2021-03-05 上海博志研新药物技术有限公司 磷酸特地唑胺及其中间体的制备方法
CN110938058B (zh) * 2018-09-22 2022-04-12 南京优科生物医药研究有限公司 一种噁唑烷酮类抗生素中间体的制备方法
CN111116652A (zh) * 2019-12-06 2020-05-08 山东中医药大学 一种高纯度磷酸特地唑胺的制备方法
CN113121518B (zh) * 2019-12-31 2022-06-28 北京福元医药股份有限公司 一种特地唑胺杂质的制备方法
CN111285848A (zh) * 2020-04-10 2020-06-16 苏州敬业医药化工有限公司 一种5-溴-2-(2-甲基-2h-四唑-5-基)吡啶的纯化方法
JP2023531666A (ja) 2020-06-18 2023-07-25 アカゲラ・メディスンズ,インコーポレイテッド オキサゾリジノン化合物、オキサゾリジノン化合物を含むリポソーム組成物、およびそれらの使用方法
CN114105946A (zh) * 2020-08-26 2022-03-01 浙江苏泊尔制药有限公司 一种磷酸特地唑胺中间体及其制备方法
CN112961186A (zh) * 2021-02-04 2021-06-15 海南通用康力制药有限公司 一种磷酸特地唑胺的纯化方法
CN113248471B (zh) * 2021-07-05 2021-09-21 南京桦冠生物技术有限公司 一种唑胺类药物中间体的制备方法及其中间体
CN113488445A (zh) * 2021-07-05 2021-10-08 合肥巨一动力系统有限公司 一种igbt封装散热结构及其应用的电机控制器

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU80081A1 (fr) 1977-08-26 1979-05-15 Delalande Sa Nouvelles hydroxymethyl-5 oxazolidinones-2,leur procede de preparation et leur application therapeutique
US4128654A (en) 1978-02-10 1978-12-05 E. I. Du Pont De Nemours And Company 5-Halomethyl-3-phenyl-2-oxazolidinones
US4340606A (en) 1980-10-23 1982-07-20 E. I. Du Pont De Nemours And Company 3-(p-Alkylsulfonylphenyl)oxazolidinone derivatives as antibacterial agents
FR2500450A1 (fr) 1981-02-25 1982-08-27 Delalande Sa Nouveaux derives aminomethyl-5 oxazolidiniques, leur procede de preparation et leur application en therapeutique
US4461773A (en) 1982-09-15 1984-07-24 E. I. Dupont De Nemours And Company P-Oxooxazolidinylbenzene compounds as antibacterial agents
CA1320730C (en) 1987-10-16 1993-07-27 The Du Pont Merck Pharmaceutical Company Aminomethyl oxooxazolidinyl aroylbenzene derivatives useful as antibacterial agents
US4948801A (en) 1988-07-29 1990-08-14 E. I. Du Pont De Nemours And Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
KR100257418B1 (ko) 1991-11-01 2000-05-15 로렌스 티. 마이젠헬더 치환된 아릴-및 헤테로아릴-페닐옥사졸리디논
SK283420B6 (sk) 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
PL175782B1 (pl) 1992-12-08 1999-02-26 Upjohn Co Nowe podstawione troponem pochodne fenylooksazolidynonowe
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
US5688792A (en) 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
EP0730591B1 (en) 1993-11-22 1999-07-14 PHARMACIA & UPJOHN COMPANY Esters of substituted-hydroxyacetyl piperazine phenyl oxazolidinones
GB9702213D0 (en) * 1996-02-24 1997-03-26 Zeneca Ltd Chemical compounds
US6413981B1 (en) 1999-08-12 2002-07-02 Ortho-Mcneil Pharamceutical, Inc. Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods
GB0009803D0 (en) 2000-04-25 2000-06-07 Astrazeneca Ab Chemical compounds
AU5889701A (en) 2000-06-05 2001-12-17 Dong A Pharm Co Ltd Novel oxazolidinone derivatives and a process for the preparation thereof
US20020115669A1 (en) 2000-08-31 2002-08-22 Wiedeman Paul E. Oxazolidinone chemotherapeutic agents
US20050032861A1 (en) 2001-04-07 2005-02-10 Betts Michael John Oxazolidines containing a sulfonimid group as antibiotics
US6627646B2 (en) 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
EP1427711B1 (en) 2001-09-11 2005-07-13 AstraZeneca AB Oxazolidinone and/or isoxazoline derivatives as antibacterial agents
GB2396350A (en) 2001-10-25 2004-06-23 Astrazeneca Ab Aryl substituted oxazolidinones with antibacterial activity
NZ515881A (en) 2001-12-03 2004-09-24 New Zealand Dairy Board Cheese flavour ingredient and method of its production
RU2004129276A (ru) 2002-02-28 2005-06-10 Астразенека Аб (Se) Производные 3-циклического-5-(азотсодержащего 5-членного кольцевого) метил-оксазолидинона и их применение в качестве антибактериальных средств
PL372090A1 (en) 2002-02-28 2005-07-11 Astrazeneca Ab Chemical compounds
US7223870B2 (en) 2002-11-01 2007-05-29 Pfizer Inc. Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
EP1567532A1 (en) 2002-11-28 2005-08-31 Astrazeneca AB Oxazolidinone and / or isoxazoline derivatives as antibacterial agents
WO2004048350A2 (en) 2002-11-28 2004-06-10 Astrazeneca Ab Oxazolidinones as antibacterial agents
GB0229518D0 (en) * 2002-12-19 2003-01-22 Astrazeneca Ab Chemical compounds
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
TW200500360A (en) 2003-03-01 2005-01-01 Astrazeneca Ab Hydroxymethyl compounds
GB0306358D0 (en) * 2003-03-20 2003-04-23 Astrazeneca Ab Chemical compounds
JP2007521283A (ja) 2003-07-02 2007-08-02 メルク アンド カンパニー インコーポレーテッド シクロプロピル基で置換されたオキサゾリジノン系抗生物質およびその誘導体
NZ544237A (en) 2003-07-02 2008-09-26 Merck & Co Inc Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof
WO2005051933A1 (en) * 2003-11-28 2005-06-09 Ranbaxy Laboratories Limited An improved process for the synthesis of 4-(4-benzyloxy-carbonylamino-2-fluorophenyl)-piperazine-1-carboxylic acid tert-butyl ester, a key intermediate for oxazolidinone antimicrobials and compounds prepared thereby
US7129259B2 (en) 2003-12-17 2006-10-31 Rib-X Pharmaceuticals, Inc. Halogenated biaryl heterocyclic compounds and methods of making and using the same
KR100854211B1 (ko) 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
US20070191336A1 (en) 2003-12-24 2007-08-16 Flynn Daniel L Anti-inflammatory medicaments
AU2005247670A1 (en) 2004-05-25 2005-12-08 Astrazeneca Ab 3- {4- (pyridin-3-yl) phenyl} -5- (1H-1, 2, 3-triazol-1-ylmethyl) -1, 3-oxazolidin-2-ones as antibacterial agents
GB0411596D0 (en) 2004-05-25 2004-06-30 Astrazeneca Ab Chemical process
US20080064689A1 (en) 2004-05-25 2008-03-13 Astrazeneca Ab 3-[4-(6-Pyridin-3-Yl)-3-Phenyl] -5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones as Antibacterial Agents
JP2008500319A (ja) 2004-05-25 2008-01-10 アストラゼネカ アクチボラグ 細菌感染症の治療のためのmao阻害剤としての3−(4−(2−ジヒドロイソオキサゾール−3−イルピリジン−5−イル)フェニル−5−トリアゾール−1−イルメチルオキサゾリジン−2−オン誘導体
MXPA06013537A (es) 2004-05-25 2007-01-26 Astrazeneca Ab 3-??4-{(alcanoil 6- substituidas) piridin-3-il}-3 -fenil!-5-(1h-1, 2, 3-triazol -1-ilmetil)-1, 3-oxazolidin- 2-onas como agentes antibacterianos.
WO2006038100A1 (en) 2004-10-08 2006-04-13 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
EP1912980A2 (en) 2005-06-20 2008-04-23 Wockhardt Limited Oxazolidinones bearing antimicrobial activity composition and methods of preparation
WO2007138381A2 (en) 2005-10-14 2007-12-06 Targanta Therapeutics Inc. Phosphonated oxazolidinones and uses thereof for the prevention and treatment of bone and joint infections
EP2185549B1 (en) 2007-08-06 2018-10-03 Micurx Pharmaceuticals, Inc. Antimicrobial ortho-fluorophenyl oxazolidinones for treatment of bacterial infections
EP2346858B1 (en) 2008-10-10 2019-08-07 Merck Sharp & Dohme Corp. Methods for preparing oxazolidinones and compositions containing them
ES2734724T3 (es) 2009-02-03 2019-12-11 Merck Sharp & Dohme Forma cristalina de dihidrogenofosfato de (R)-3-(4-(2-(2-metiltetrazol-5-il)piridin-5-il)-3-fluorofenil)-5-hidroximetiloxazolidin-2-ona
US8580767B2 (en) 2009-05-28 2013-11-12 Trius Therapeutics, Inc. Oxazolidinone containing dimer compounds, compositions and methods to make and use

Also Published As

Publication number Publication date
RU2556234C2 (ru) 2015-07-10
CA2738671C (en) 2018-05-01
HK1232221A1 (zh) 2018-01-05
US8604209B2 (en) 2013-12-10
JP5773875B2 (ja) 2015-09-02
EP2346858A2 (en) 2011-07-27
CN102177156B (zh) 2016-08-24
WO2010042887A2 (en) 2010-04-15
CN106220621A (zh) 2016-12-14
CN102177156A (zh) 2011-09-07
RU2659792C1 (ru) 2018-07-04
CN106220621B (zh) 2019-06-11
MX2011003820A (es) 2011-06-16
ES2748505T3 (es) 2020-03-17
SG10201702946RA (en) 2017-05-30
MX366793B (es) 2019-07-24
EP2346858B1 (en) 2019-08-07
EP2757104B1 (en) 2019-08-14
US20140206878A1 (en) 2014-07-24
ES2744907T3 (es) 2020-02-26
US20100093669A1 (en) 2010-04-15
KR101674146B1 (ko) 2016-11-08
CA2738671A1 (en) 2010-05-15
SG195544A1 (en) 2013-12-30
US9328087B2 (en) 2016-05-03
AU2009303301A1 (en) 2010-04-15
RU2011115109A (ru) 2012-11-20
WO2010042887A3 (en) 2010-06-24
AU2009303301B2 (en) 2014-09-11
JP2012505252A (ja) 2012-03-01
KR20110071107A (ko) 2011-06-28
EP2757104A1 (en) 2014-07-23

Similar Documents

Publication Publication Date Title
HK1200169A1 (en) Compounds used in the synthesis of oxazolidinones
HRP20180718T1 (hr) Oligopeptidni spojevi i njihova upotreba
IL254218A0 (en) Pipedrine-bridged compounds of the quinoxaline-converted type and their use
HK1139936A1 (en) Substituted pyrimidodiazepines useful as plk1 inhibitors
EP2251403A4 (en) CLEANING SUPPLIES
IL212590A0 (en) New compounds 578
HK1179514A1 (en) Composition for external use
HK1154794A1 (en) Liquid oral composition
GB0808708D0 (en) New compounds 274
GB0808707D0 (en) New compounds 275
ZA201103888B (en) Novel use
GB0823366D0 (en) Synthesis
GB0800414D0 (en) Novel use
PL384700A1 (pl) Sposób syntezy 1-propenyloksyalkoholu
GB0811131D0 (en) Novel compounds 336
GB0803103D0 (en) Novel compounds 3
GB0807162D0 (en) Novel use
GB0823010D0 (en) Novel use
GB0822377D0 (en) Novel use
GB0814821D0 (en) Novel use
GB0805046D0 (en) Novel use
GB0801110D0 (en) Synthesis
GB0813324D0 (en) New compounds 3
GB0807658D0 (en) Sebaforce 2
GB0808845D0 (en) 10000003